NCT00649168View on ClinicalTrials.gov

Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Healthy
Interventions
DRUG

BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg

2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection

DRUG

Parlodel® (bromocriptine mesylate) capsules, USP 5 mg

2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection

Trial Locations (1)

H4R 2N6

MDS Pharma Services, Montreal

Sponsors
All Listed Sponsors
lead

Mylan Pharmaceuticals Inc

INDUSTRY

NCT00649168 - Fed Study of (Parlodel®) Bromocriptine Mesylate Capsules 5 mg | Biotech Hunter | Biotech Hunter